The expansion will include Ripple’s Epidel platform, which delivers sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients, according to a March 20 news release from Hovione.
Epidel enables higher drug loading, smaller size implants, and defined and predictable biocompatible degradation products, the release said.
By incorporating Epidel, Hovione can expand its portfolio throughout the pharmaceutical industry, according to the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
